-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer Partners with Soufflé Therapeutics to Develop siRNA Therapy for Rare Heart Disease

MT Newswires·01/08/2026 03:53:14
Listen to the news
03:53 AM EST, 01/08/2026 (MT Newswires) -- Bayer (BAYN.F) said Thursday it entered into a strategic collaboration and global licensing deal with the US-based biotech company Soufflé Therapeutics to develop a heart-targeted small interfering RNA therapy. The partners will develop the treatment for a form of dilated cardiomyopathy, a rare form of heart disease. The German company previously invested in Soufflé Therapeutics through its Leaps by Bayer initiative. Financial terms of the deal were not disclosed.